Adalimumab therapy in rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 30, Issue 2, 2004, Pages 349-364

  Keystone, Edward ^a   Haraoui, Boulos ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Rehabilitation Institute of Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE;

ASPERGILLOSIS; BACTERIAL INFECTION; CARCINOGENESIS; CLINICAL TRIAL; DEMYELINATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FERTILITY; HEADACHE; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; MUTAGENESIS; NONHUMAN; OPTIC NERVE DISEASE; PARESTHESIA; PREGNANCY; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; TREATMENT CONTRAINDICATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2542474187     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2004.02.004     Document Type: Review

References (22)

1. Salfeld J., Kaymakçalan Z., Tracey D., Roberts A., Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract 147]. Arthritis Rheum. 41(Suppl):1998;S57
2. Emery P., van de Putte L.B.A., van Riel P.L.C.M., Rau R., Schattenkirchner M., Burmester G.R., et al. Changes in Pro-MMP-1 in relation to standard measures of disease activity over a 6-month treatment period with adalimumab (D2E7) in rheumatoid arthritis [abstract 976]. Arthritis Rheum. 44(Suppl):2001;S215
3. Breedveld F.C., Allaart C.F., Rau R. The fully human anti-TNF antibody adalimumab (D2E7) in combination with MTX in the treatment of active rheumatoid arthritis: results of a 2-year study [abstract 0P0062]. Ann Rheum Dis. 60(Suppl):2001;S278
4. Rau R., Herborn G., Sander O., van de Putte L.B.A., van Riel P.L.C.M., den Broeder A., et al. Long term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis [abstract 1978]. Arthritis Rheum. 42(Suppl):1999;S400
5. Schattenkirchner M., Krüger K., Sander O., Rau R., Kroot E.J., van Riel P.L.C.M., et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis - results of a phase I study [abstract 149]. Arthrits Rheum. 41(Suppl):1998;S57
6. Rau R., Sander O., den Broeder A., Van Riel P., van der Putte L., Kruger K., et al. Long term efficacy and tolerability of multiple IV doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract 137]. Arthritis Rheum. 41(Suppl):1998;S55
7. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48:2003;35-45
8. Keystone E., Kavanaugh A., Sharp J., Hua Y., Teoh L., Fischkoff S., Chartash E. Adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody inhibits the progression of structure joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum. 46(Suppl 9):2002;S205
9. van de Putte L., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.C.L., et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum. 46(Suppl 9):2002;S205
10. Strand V., Weisman M.H., Nichol M.D., Knight T.K., Cohang K., Chartash E.K. Humira (adalimumab) improves health-related quality of life in rheumatoid arthritis patients. Ann Rheum Dis. 62(Suppl I):2003;S356
11. Weisman M.H., Nichol M.B., Knight T.K., Boggs R.L., Chartash E.K. The importance of pain and the impact of adalimumab on pain in rheumatoid arthritis patients [abstract SAT0231]. Ann Rheum Dis. 62(Suppl I):2003;S351
12. Emery P., Fleischmann R., Strand V., Reiss W.G., Fischkoff S.A., Spencer-Green G.T. Improvement in HAQ disability in rheumatoid arthritis (RA) with adalimumab (HUMIRA™) based on duration of disease [abstract 737]. Arthritis Rheum. 48(Suppl):2003;S313
13. Chartash E.K., Vasey F.B., Young S., Cella D., Sengupta N. Adalimumab improves fatigue in patients with active rheumatoid arthritis [abstract SAT0225]. Ann Rheum Dis. 62(Suppl I):2003;349
14. Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E., Fischkoff S. Subgroup analysis of radiographic progression in RA patient treated with adalimumab [abstract THU0198]. Ann Rheum Dis. 62(Suppl I):2003;169
15. Breedveld F.C., Rau R., van Riel P.L.C., van de Putte L.B.A., Schattenkirchner M., Kupper H. Sustained efficacy over 5 years with adalimumab (Humira™) in patients with active rheumatoid arthritis [abstract 198]. Arthritis Rheum. 48(Suppl 9):2003;S118
16. Schiff M.H., Weisman M.H., Furst D.E., Kavanaugh A., Fischkoff S.A., Spencer-Green G.T. Sustained efficacy of adalimumab (Humira™) plus methotrexate in rheumatoid arthritis (RA). Arthritis Rheum. 48(Suppl 9):2003;S314
17. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A., Segurado O.G., Fischkoff S.A., et al. Sustained improvement and Tolerability in long-term follow up of patients treated with adalimumab (Humira™) [abstract 738]. Arthritis Rheum. 48(Suppl 9):2003;S314
18. Keystone E.C., Kavanaugh A., Sharp T., Spencer-Green G.T., Fischkoff S.A. Sustained radiographic inhibition with adalimumab (Humira™) over 2 years in patients with long standing rheumatoid arthritis (RA) [abstract 741]. Arthritis Rheum. 48(Suppl 9):2003;S315
19. van de Putte L.B.A., Rau R., Burmester G.R., Hartz D., Fischkoff S.A., Kupper H., et al. Sustained 5 year efficacy of adalimumab (Humira™) monotherapy in DMARD refractory rheumatoid arthritis (RA) [abstract 739]. Arthritis Rheum. 48(Suppl 9):2003;S314
20. Keystone E., Kavanaugh A., Fischkoff S. Response to adalimumab in patients with early versus late rheumatoid arthritis (RA). Ann Rheum Dis. 63(Suppl 1):2003;170
21. Furst D., Schiff M., Fleischmann R., Birbara C., Strand V., Compagnone D., et al. Adalimumab, a fully human monoclonal antibody for the treatment of rheumatoid arthritis (STAR) [abstract 1537]. Arthritis Rheum. 46(Suppl):2002;S572
22. Kavanaugh A.F., Greenwald M., Zizic T., Rao V., Fischkoff F., Hoffman R., et al. Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract 259]. Arthritis Rheum. 46(Suppl):2002;S132